Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
Abstract Background Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combination chemotherapy is more effective than the standard adjuvant chemothe...
Main Authors: | Tsutomu Namikawa, Hiromichi Maeda, Hiroyuki Kitagawa, Koji Oba, Akihito Tsuji, Takaki Yoshikawa, Michiya Kobayashi, Kazuhiro Hanazaki |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4109-z |
Similar Items
-
Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
by: Yu S, et al.
Published: (2020-10-01) -
Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
by: Guoxiu Wang, et al.
Published: (2018-05-01) -
Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01) -
Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
by: Diana Groza, et al.
Published: (2018-05-01) -
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study
by: Tsuruta A, et al.
Published: (2016-11-01)